Capricor Therapeutics (CAPR) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Evolus (EOLS) over the past year, gaining 32.0% versus a loss of 4.8%. Over five years, CAPR leads with a +122.6% price change compared with +14.4% for EOLS. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | EOLS |
|---|---|---|
| Share price | $7.59 | $6.52 |
| Market cap | $441.30M | $431.55M |
| 1-day change | +0.80% | -6.86% |
| YTD return | -73.70% | -1.95% |
| 1-year return | +32.00% | -4.82% |
| 5-year return | +122.58% | +14.39% |
| Forward P/E | — | 22.68 |
| EPS (TTM) | $-2.65 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $297.18M |
| Revenue growth (YoY) | -100.00% | +11.61% |
| Net income (latest FY) | $-105.04M | $-51.64M |
| Gross margin | — | 66.33% |
| Operating margin | — | -10.99% |
| Net margin | — | -17.38% |
| 52-week high | $40.37 | $9.31 |
| 52-week low | $2.96 | $3.86 |
| Distance from 52-week high | -81.20% | -29.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +259.03% | +136.20% |
| Average volume | 4.73M | 925.77K |
| Shares outstanding | 58.14M | 66.19M |
| Employees | 231 | 365 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed EOLS by 36.8 percentage points over the past year.
- Evolus grew revenue faster in its latest fiscal year (+11.61% vs -100.00%).
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
CAPR vs EOLS FAQ
Which is bigger, Capricor Therapeutics or Evolus?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $431.55M for Evolus (EOLS).
Which stock has performed better over the past year, CAPR or EOLS?
CAPR returned +32.00% over the past 12 months, compared with -4.82% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.